Filter Results
Clinical Studies
Results filtered:Study status:
Open
Closed for Enrollment
Open
-
A Phase 1b, Multicenter, Open-Label, Dose Finding Study to Investigate the Safety and Tolerability of a Single Intravenous Dose of SGT-501 in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia (ARTEMIS)
Rochester, Minn.
The purpose of this study is to investigate the safety and tolerability of a single intravenous (IV) dose of SGT-501.
-
Evaluation of a Novel Diagnostic Test for Calcium Release Deficiency Syndrome
Rochester, Minn.
The purpose of this study is to investigate the response to either an atrial or ventricular pacing train as a diagnostic test for Calcium Release Deficiency Syndrome (CRDS).
-
First-in-Human, Open-Label, Safety, Tolerability, Dose Finding, Pharmacodynamic And Cardiac Transgene Expression Study Of TN-401, A Recombinant Adeno-associated Virus Serotype 9 (AAV9) Containing Plakophilin-2 (PKP2) Transgene, In Adults With PKP2 Mutation-associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
Rochester, Minn.
The purpose of this study is to evaluate the safety, tolerability, and pharmacodynamics (PD) of TN-401 in adult patients with symptomatic PKP2 mutation-associated ARVC. The trial will consist of 2 escalating dose cohorts. All patients will receive active drug.
-
First-in-Human, Open-Label, Safety, Tolerability, Dose-Finding, Pharmacodynamic And Cardiac Transgene Expression Study Of TN-201, A Recombinant Adeno-associated Virus Serotype 9 (AAV9) Containing Myosin Binding Protein C Transgene, In Adults With MYBPC3 Mutation-associated Hypertrophic Cardiomyopathy (HCM) (MyPEAK-1)
Rochester, Minn.
This is a first-in-human, non-randomized, open-label study designed to evaluate the safety, tolerability, and pharmacodynamics (PD) of TN-201 in adult patients with symptomatic hypertrophic cardiomyopathy (HCM) caused by mutations in the MYBPC3 gene.
-
International CRDS Registry
Rochester, Minn.
The purpose of this research study is to establish a large registry of individuals diagnosed with CRDS, along with individuals that have genetic changes that could potentially place them at risk for a CRDS-like condition, from around the world.
.